Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

IDL Biotech: Showing progression in line with investment case

2019-08-23

12:33

LS

Ludvig Svensson

We provide a short research update with the latest financial estimates and valuation following IDL Biotech’s Q2’19 report. We factor in higher gross margins and slightly lower costs related to SG&A in near-term, which has a positive effect on our valuation. Our new base case amounts to SEK 3.8 per share, with a Bull and Bear Case of SEK 7.4 and 1.5 per share, respectively.

Disclosures and disclaimers